Judge Denies Teva Pharmaceuticals’ Motion to Dismiss Corcept Therapeutics’ Allegations of Patent Infringement
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: GlobeNewswire
MENLO PARK, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today announced that Judge Susan Wigenton of the United States District Court for the District of New Jersey has denied Teva Pharmaceuticals USA, Inc.’s motion to dismiss a lawsuit brought by Corcept alleging infringement of patents relating to the use of Korlym®, Corcept’s medication for the treatment of patients with endogenous Cushing’s syndrome. Corcept has sued Teva for infringement of two patents covering Korlym upon receipt of notice in February 2018 that Teva is seeking approval from the United States Food & Drug Administration to market a generic version of Korlym. In July 2018, Corcept filed an amended complaint asserting a third patent against Teva. Judge Wigenton’s den
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Corcept Therapeutics: Key Catalysts Ahead [Seeking Alpha]Seeking Alpha
- Corcept Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow [Yahoo! Finance]Yahoo! Finance
CORT
Earnings
- 2/15/24 - Beat
CORT
Sec Filings
- 3/27/24 - Form SC
- 3/27/24 - Form 144
- 3/20/24 - Form 4
- CORT's page on the SEC website